Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-6.21%127.720.7%$1062.40m
MRKMerck & Co., Inc.
1.07%84.700.7%$636.75m
PFEPfizer Inc.
0.00%36.460.9%$629.75m
ABBVAbbVie, Inc.
1.77%76.472.3%$578.88m
BMYBristol-Myers Squibb Company
1.15%53.021.4%$522.05m
LLYEli Lilly and Company
0.16%108.631.0%$298.35m
NVSNovartis AG Sponsored ADR
-0.39%86.890.2%$144.58m
AZNAstraZeneca PLC Sponsored ADR
-0.59%43.871.2%$133.90m
GSKGlaxoSmithKline plc Sponsored ADR
0.12%42.520.2%$97.15m
SNYSanofi Sponsored ADR
-0.71%46.170.2%$75.70m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.29%52.530.1%$68.10m
LCILannett Company, Inc.
-1.84%11.7335.6%$15.44m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.87%1.691.6%$0.44m
EPIXESSA Pharma Inc
8.79%3.900.1%$0.11m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.